ReviewMaterials today. Bio2023
Multifunctional nanostructures: Intelligent design to overcome biological barriers.
Review in Materials today. Bio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Next-generation biomedical nanorobots: active design, intelligent control, and translational opportunities in regenerative and minimally invasive medicine.Journal of nanobiotechnology · 2026Review
- Harnessing nature's blueprint: Unlocking the potential of subcellular structure membrane-coated nanosystems for precision medicine.Bioactive materials · 2026Review
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Glutathione-responsive deformable manganese-based nanomedicines for enhanced tumor-specific chemotherapy.RSC advances · 2026Article
- Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery.Pharmaceutics · 2026Review
- Engineering combination nanomedicines to overcome cancer resistance.RSC advances · 2026Review
- Rewriting Tumor Entry Rules: Microfluidic Polyplexes and Tumor-Penetrating Strategies-A Literature Review.Pharmaceutics · 2026Review
- Nanoparticle delivery systems for HIV pre-exposure prophylaxis (PrEP): advances and challenges.Beilstein journal of nanotechnology · 2026Review
- Ubiquitination regulation in coronary microcirculation dysfunction: focus on the endothelial cells.Frontiers in cardiovascular medicine · 2026Review
- Niosome-loaded silibinin and methotrexate for synergistic breast cancer combination chemotherapy: in silico and in vitro study.Cancer cell international · 2025Article
- Artificial Intelligence-Driven Nanoarchitectonics for Smart Targeted Drug Delivery.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Special Issue "Biopolymers in Drug and Gene Delivery Systems 3.0".International journal of molecular sciences · 2025Article
- Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Dual-loaded niosome-dendrimer nanoplatform enhances Tirapazamine delivery to hypoxic breast cancer cells.Scientific reports · 2025Article
- Daptomycin-Loaded Nano-Drug Delivery System Based on Biomimetic Cell Membrane Coating Technology: Preparation, Characterization, and Evaluation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Organ-on-chip platforms for nanoparticle toxicity and efficacy assessment: Advancing beyond traditional in vitro and in vivo models.Materials today. Bio · 2025Review
- Curcumin and Silibinin loaded pegylated nanoniosome for cancer therapy: bioinformatics and in vitro study.Molecular biology reports · 2025Article
- Tumor Microenvironment Responsive TPZ-Loaded Core-Shell Polymeric Nanoparticles for Selective Cancer Bioreductive Therapy.Advanced pharmaceutical bulletin · 2025Article
- Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis.Medical oncology (Northwood, London, England) · 2025Article
- Poloxamer-based drug delivery systems: Frontiers for treatment of solid tumors.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past three decades, nanoscience has offered a unique solution for reducing the systemic toxicity of chemotherapy drugs and for increasing drug therapeutic efficiency. However, the poor accumulation and pharmacokinetics of nanoparticles are some of the key reasons for their slow translation into the clinic. The is intimately linked to the non-biological nature of nanoparticles and the aberrant features of solid cancer, which together significantly compromise nanoparticle delivery. New findings on the unique properties of tumors and their interactions with nanoparticles and the human body suggest that, contrary to what was long-believed, tumor features may be more mirage than miracle, as the enhanced permeability and retention based efficacy is estimated to be as low as 1%. In this review, we highlight the current barriers and available solutions to pave the way for approved nanoformulations. Furthermore, we aim to discuss the main solutions to solve inefficient drug delivery with the use of nanobioengineering of nanocarriers and the tumor environment. Finally, we will discuss the suggested strategies to overcome two or more biological barriers with one nanocarrier. The variety of design formats, applications and implications of each of these methods will also be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.